Physician profile
Michael R Wild
NPI 1437110541
$1,281.24
in general payments reported to CMS, 2019-2025
16 companies · $33.41 in 2025
The $33.41 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $163 · 2021: $40.47 · 2022: $307 · 2023: $106 · 2024: $239 · 2025: $33.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.62 | 2022-2025 | Durysta, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $207.47 | 2019 | |
| Allergan, INC. | $200.25 | 2019-2021 | |
| Glaukos Corporation | $146.16 | 2024 | Idose |
| Aerie Pharmaceuticals, INC. | $122.09 | 2019 | |
| Alcon Vision LLC | $94.34 | 2019-2023 | Rocklatan, Simbrinza |
| Genentech USA, INC. | $72.44 | 2022-2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $37.56 | 2019-2022 | |
| Horizon Therapeutics Plc | $34.25 | 2022-2023 | Tepezza |
| Dompe US, INC. | $32.99 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $23.98 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.99 | 2019 | |
| Amgen INC. | $15.96 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $15.19 | 2023 | Syfovre |
| Ivantis, INC | $13.83 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.